PTC THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
PTC THERAPEUTICS INC. - More news...
PTC THERAPEUTICS INC. - More news...
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
- PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
- PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
- PTC Therapeutics to Participate in Upcoming Investor Conferences
- PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
- PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
- PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
- PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
- CHMP Maintains Negative Opinion on Translarna™ Reexamination
- PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
- PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
- PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
- FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
- PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
